以证据医学(EBM)为基础的谷氨酰胺和肠通透性的临床研究

Principle of evidence-based medicine and its application in clinical trial practice for glutamine and gut permeability

以证据医学(evidence-based medicine)为基础的临床研究并不是取代所有的传统临床研究模式,但它将是21世纪临床研究的发展方向。证据医学着重以客观的终点指标、病人的预后(病死率、并发症发生率和住院时间等)、生活质量及如功/耗比等来评价某一种治疗方法或某一种药物的效果。证据医学以病人获得实际益处为中心,如降低死亡率,减少并发症,提高病人的生活质量等。该评价方法已日益增多地应用于发达国家的临床研究中,对我们的临床研究有重要指导意义。文献附有观察谷氩酰胺双肽对肠道粘膜通透性,术后与感染有关的并发症及住院时间等影响的实例。观察到谷氨酰胺双肽强化的肠外营养有助于肠粘膜通透性的维持,减少与感染有关的并发症及缩短住院日等效应。

Evidence-based medicine (EBM) was the progress of traditional clinical trial model. EBM was based on well-designed, randomized, double blind, controlled, multiple center trials in order to assess end point parameters, prognosis parameters (as: mortality, morbidity of complications and hospital stay etc. ), quality of life and cost/effecl ratio. It has been accepted in developed countries and should be the guidelines for Chinese clinical trials in the future. This article summarized the principle of EBM and attached with a clinical trial sample about effects of glutamine dipeptide (Diepeliven) on gut barrier function, post-operative complications and the hospital stay.